

10/713,722


* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:18:31 ON 26 MAY 2005

=> file reg

$$\Rightarrow$$

Uploading C:\Program Files\Stnexp\Queries\10713722.str



chain nodes :

1 2 3 4 5 10 11 12 13 14 15 16 17

chain bonds :

1-2 2-3 3-4 4-5 5-10 10-11 11-12 11-13 12-14 12-16 13-15 13-17

exact/norm bonds :

1-2 2-3 3-4 4-5 5-10 12-14 12-16 13-15 13-17

exact bonds :

10-11 11-12 11-13

G1: O, S, N

Match level :

```
1:Atom  2:CLASS  3:CLASS  4:CLASS  5:Atom  10:CLASS  11:CLASS  12:CLASS  13:CLASS
```


14:CLASS 15:CLASS 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1	STR
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100



G1 O,S,N

10/713,722

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 14:18:57 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 780176 TO ITERATE

44.8% PROCESSED 349280 ITERATIONS

31 ANSWERS

51.3% PROCESSED 400000 ITERATIONS

31 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.36

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**

BATCH **INCOMPLETE**

PROJECTED ITERATIONS: 780176 TO 780176

PROJECTED ANSWERS: 37 TO 83

L3 31 SEA SSS FUL L1

=> file ca

=> s l3



L4 5 L3

=> d ibib abs hitstr 1-5

10/713,722


L4 ANSWER 1 OF 5 CA COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 142:373683 CA
 TITLE: Preparation of 1,3-diketone compounds useful for treatment of diabetes, obesity and hyperlipidemia
 INVENTOR(S): Yang, Yushu; Tang, Lei; Ji, Ruyun; Chen, Kaixian; Sun, Piaoyang
 PATENT ASSIGNEE(S): Shanghai Institute of Pharmacy, Chinese Academy of Sciences, Peop. Rep. China; Hengrui Medicine Co., Ltd., Jiangsu
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 25 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1478770	A	20040303	CN 2002-136715	20020829
PRIORITY APPLN. INFO.: GI			CN 2002-136715	20020829




AB Title compds. I [wherein R1, R2 = alkyl, alkoxy, alkylamino, heterocyclic amino, hydrazino, etc.; R3 = -CH2OH, -CO2CH3, -CH2OCH3 or H; R4 = certain (un)substituted indolyl or pyridinylamino; n = 1-6, with some limitations] were prepared for instance, condensation of 4-[2-(N-methyl-2-pyridinylamino)ethoxy]benzaldehyde with di-Me malonate in toluene followed by Pd/C-catalyzed hydrogenation of the resultant alkene with H2 in methanol-dioxane gave II in 59.1% yield (for two steps). Some I showed strong insulin-sensitizing activity. Therefore, I are useful in the treatment of type II diabetes, obesity and hyperlipidemia.
 IT 610280-91-6P 610280-92-7P 610280-94-8P
 610280-96-1P 610280-97-2P 610280-99-4P
 610281-01-1P 610281-03-3P 610281-05-5P
 610281-07-7P 610281-08-8P


L4 ANSWER 1 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)




RN 610280-97-2 CA
 CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(4-pyridinylamino)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 610280-99-4 CA
 CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(2-pyridinylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 610281-01-1 CA
 CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(3-pyridinylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 610281-03-3 CA
 CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(4-pyridinylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BLOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate) prepn. of 1,3-diketone compds. with insulin-sensitizing activity
 RN 610280-91-6 CA
 CN Propanediamide, N,N'-dihydroxy-2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 610280-92-7 CA
 CN Propanedioic acid, [[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, dihydrazide (9CI) (CA INDEX NAME)




RN 610280-94-9 CA
 CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(2-pyridinylamino)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 610280-96-1 CA
 CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]-α-[(3-pyridinylamino)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)




RN 610281-05-5 CA
 CN Propanediamide, N,N'-dimethyl-2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 610281-07-7 CA
 CN Propanediamide, 2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-N,N'-diphenyl- (9CI) (CA INDEX NAME)



RN 610281-08-8 CA
 CN Propanediamide, N,N'-dicyclopropyl-2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 5 CA COPYRIGHT 2005 ACS ON STM
ACCESSION NUMBER: 141:173856 CA
TITLE: Design, synthesis, and evaluation of a new class of
nonycyclic 1,3-dicarbonyl compounds as PPAR α
selective activators
AUTHOR(S): Li, Zhibin; Liao, Chenzhong; Ko, Ben C. B.; Shan,
Song; Tong, Edith H. Y.; Yin, Zihui; Fan, Desi; Wong,
Vincent K. W.; Shi, Leming; Ning, Zhi-Qiang; Hu,
Weiming; Zhou, Jiaju; Chung, Stephen S. M.; Lu,
Xian-Ping
CORPORATE SOURCE: Chipscreen Biosciences, Ltd, Research Institute of
Tsinghua University, Shenzhen, 518057, Peop. Rep. China
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004),
14(13), 3507-3511
CODEN: BMCLEL; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:173856
GI




AB Lipid accumulation in nonadipose tissues is increasingly linked to the development of type 2 diabetes in obese individuals. The design, synthesis, and evaluation of a series of novel PPAR α selective activators containing 1,3-dicarbonyl moieties. Structure-activity relationship studies led to the identification of PPAR α selective activators with stronger potency and efficacy to activate PPAR α over PPAR β and PPAR γ . Expts. in vivo showed that compds. 1, II, and I (R1, R2 = CH₃, R3, R4, R2 = NH₂) had blood glucose lowering effect in diabetic db/db mice after two weeks oral dosing. The data strongly support further testing of these lead compds. in other relevant disease animal models to evaluate their potential therapeutic benefits.

IT 701294-91-9P 701294-92-0P 701294-93-1P
701294-94-2P 701294-97-5P 701294-39-7P
701294-41-1P 701294-45-5P 701294-46-1P
736171-91-8P 736171-93-0P 736171-94-6P
736171-95-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compds. as PPAR α selective activators for the

14	ANSWER 2 OF 5	CA	COPYRIGHT 2005 ACS on STN
	ACCESSION NUMBER:		142:177008 CA
	TITLE:		Mono- and Bivalent Ligands Bearing Mannose 6-Phosphate (M6P) Surrogates: Targeting the M6P/Insulin-Like Growth Factor II Receptor
	AUTHOR(S):		Berkovitz, David B.; Maiti, Gourhari; Charette, Bradley D.; Dreis, Christine D.; MacDonald, Richard G.
	CORPORATE SOURCE:		Department of Chemistry, University of Nebraska, Lincoln, NE 68588-0304, USA
	SOURCE:		Organic Letters (2004) 4:26, 4921-4924 CODIN: ORLETT ISSN: 1523-7060
	PUBLISHER:		American Chemical Society
	DOCUMENT TYPE:		Journal
	LANGUAGE:		English
AB	Mannose 6-phosphate mimics locked into the α -configuration and bearing hydrolase-resistant phosphate surrogates were synthesized and evaluated for binding affinity to the mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R). Affinity increases as the phosphate surrogate is varied in the order malonate < malonate < phosphonate. An alkaline hydrolysis approach to sought after bivalent M6P-bearing ligands is also described. These compds. were designed to map onto biotransport sectors of high-mannose-type oligosaccharides carried by glycoprotein M6P/IGF2R ligands. 66472069H.		
IT	833489-25-1P RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (mono and bivalent ligands bearing mannose phosphate m surrogates targeting mp insulinlike growth factor ii receptor)		
RN	833489-25-1 CA		
CN	α -D-mannocotropyranosiduronic acid, 1,4-butanediyl bis[7-carboxy-6,7-dideoxy-, tetraammonium salt (SCI) (CA INDEX NAME)		
Absolute stereochemistry. Rotation (+).			




REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 3 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)
RN treatment of diabetes
701294-91-9
CN Propanedioic acid, [[4-[2-[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]oxy]ethoxy]phenyl]methyl]-, monomethyl ester (SCI) (CA INDEX NAME)



RN 701294-92-0 CA
CN Propanedioic acid, [[4-[2-[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]oxy]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 701294-93-1 CA
CN Benzenepropanoic acid, α -(aminocarbonyl)-4-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 701294-94-2 CA
CN Benzenepropanoic acid, α -(aminocarbonyl)-4-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]ethoxy]- (9CI) (CA INDEX NAME)

10/713,722


L4 ANSWER 3 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)




RN 701294-97-5 CA
 CN Benzenepropanoic acid, α -(aminocarbonyl)-4-[2-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 701979-39-7 CA
 CN Propanedioic acid, [[4-[2-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)




RN 701979-41-1 CA
 CN Propanedioic acid, [[4-[2-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 701979-45-5 CA
 CN Propanedioic acid, [[4-[2-(2-naphthalenyloxy)ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)




RN 736171-95-2 CA
 CN Benzenepropanoic acid, α -(aminocarbonyl)-4-[2-[(1,2,3,4-tetrahydro-6-quinolinyloxy]ethoxy]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 3 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)




RN 701979-46-6 CA
 CN Benzenepropanoic acid, α -(aminocarbonyl)-4-[2-(2-naphthalenyloxy)ethoxy]- (9CI) (CA INDEX NAME)



RN 736171-91-8 CA
 CN Propanedioic acid, [[4-[2-(2-naphthalenyloxy)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 736171-93-0 CA
 CN Propanedioic acid, [[4-[2-[(1,2,3,4-tetrahydro-6-quinolinyloxy]ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)



RN 736171-94-1 CA
 CN Propanedioic acid, [[4-[2-[(1,2,3,4-tetrahydro-6-quinolinyloxy]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 5 CA COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 141:38535 CA
 TITLE: Preparation of noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
 INVENTOR(S): Lu, Xian-Ping; Li, Zhibin; Liao, Chenzhong; Shi, Leming; Liu, Zhende; Ning, Zhiqiang; Shan, Song; Deng, Tuo; Ma, Baoshun
 PATENT ASSIGNEE(S): Shenzhen Chipscreen Biosciences Ltd., Peop. Rep. China
 SOURCE: PCT Int. Appl., 57 pp.
 DOCUMENT TYPE: CODEN: PIXX2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048338	A1	20040610	WD 2003-1B5294	20031119
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZH, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZH, ZW, AM, AZ, BY, EG, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004138211	A1	20040715	US 2003-713722	20031114
PRIORITY APPLN. INFO.:			US 2002-429294P	P 20021126
			US 2003-713722	A 20031114
OTHER SOURCE(S):			MARPAT 141:38535	

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed are the preparation and pharmaceutical use of novel noncyclic 1,3-dicarbonyl compds. I (ring A (fused to ring B) = (un)substituted, (un)saturated 5- or 6-membered ring optionally containing 1 or more of O, S, N (optionally substituted with one or more halogen, OH, NO₂, CN, alkyl, alkenyl, alkenynyl, aralkyl, heteroaryalkyl, aminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, hydroxyalkyl, thioalkyl, heterocyclyl, alkoxy, aryl, aryloxy, aralkoxy, heteroaryl, heteroaryloxy, heteroalkoxy, acyl, acyloxy, NH₂, alkylamino, arylamino, aralkylamino); ring B (fused to ring A) = (un)substituted, (un)saturated 5- or 6-membered ring optionally containing 1 or more of O, S, N (optionally substituted as

in A): R₁, R₂, R₃ = H, alkyl, alkenyl, alkenynyl, aralkyl, heteroaryalkyl, aminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, hydroxyalkyl, thioalkyl, heterocyclyl, OH, halogen, alkoxy, aryl, aryloxy, aralkoxy, heteroaryl, heteroaryloxy, heteroalkoxy, acyl, acyloxy, NH₂, alkylamino, arylamino, aralkylamino; R₄, R₅ = H, alkyl, alkenyl, alkenynyl, aralkyl, heteroaryalkyl, heterocycle, aryl, heteroaryl; X, Y = O, S, NR₆; R₆ = H, Cl-3-alkyl; Q, Z = O, S, NR₇; R₇ = H, alkyl, aryl, arylalkyl; Ar = (un)substituted arylene, heteroarylene, divalent heterocycle (optionally substituted with halogen, Cl-6-alkyl, NH₂, OH, Cl-6-alkoxy, aryl); n = 1

L4 ANSWER 4 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)


-6], their stereoisomers, enantiomers, diastereomers, hydrates or pharmaceutically acceptable salts. A process for the prepn. of I is characterized by: (a) reaction of bicyclic compd. II with 4-(BrCH₂CH₂O)C₆H₄CHO in the presence of KOH; (b) Knoevenagel reaction of benzaldehyde III with CH₂(CO₂Me)₂ in the presence of catalytic piperidinium acetate; (c) catalytic hydrogenation of benzylidene III with H₂ in the presence of Pd/C to give benzylmalonates V; (d) the other 1,3-dicarbonyl compds. I are prepd. via hydrolysis or other conventional reactions. Thus, malonamide I [AB = 6-quinolinyl, X = O, n = 2, Y = O, Ar = 1,4-phenylene, R₁-R₃ = H, ZR₄ = OH, QR₅ = NH₂ (VI)] was prepd. from 6-quinolinol via etherification with 4-(BrCH₂CH₂O)C₆H₄CHO in EtOH contg. KOH, Knoevenagel condensation with CH₂(CO₂Me)₂ in PhMe contg. catalytic piperidinium acetate, catalytic hydrogenation in EtOH in the presence of Pd/C, partial hydrolysis with aq. NaOH in THF/MeOH, amidation (SOCl₂ in C₆H₆ then 28% ammonia soln.) and sapon. with aq. NaOH in THF/MeOH. These compds., as peroxisome proliferator-activated receptor (PPAR) dual agonists for both RXR/PPAR γ and RXR/PPAR α heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and assoc. metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders. Agonist activity of VI (AB = quinoline, X = 6-O, n = 2, Y = O, Ar = 1,4-phenylene, R₁-R₃ = H, ZR₄ = OH, QR₅ = NH₂) vs. RXR/PPAR γ and RXR/PPAR α heterodimers studied (see graphs).

IT 701294-91-9P 701979-39-7P 701979-45-5P 701979-48-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and amidation of; preparation of noncyclic 1,3-dicarbonyl compds. as dual PPAR agonists with antihyperglycemic and antihyperlipidemic activity)

RN 701294-91-9 CA


CN Propanedioic acid, [[4-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)



RN 701979-39-7 CA


CN Propanedioic acid, [[4-[2-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)




RN 701294-97-5 CA

CN Benzenepropanoic acid, alpha-(aminocarbonyl)-4-[2-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 701295-01-4 CA

CN Benzenepropanoic acid, alpha-(aminocarbonyl)-4-[2-[(2-naphthalenyl)oxy]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 701295-04-7 CA

CN Benzenepropanoic acid, alpha-(aminocarbonyl)-4-[2-[(1,2,3,4-tetrahydro-7-quinolinyl)oxy]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)




IT 701294-92-0P 701294-94-2P 701294-98-6P 701979-41-1P 701979-46-6P 701979-49-9P

L4 ANSWER 4 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)




RN 701979-45-5 CA

CN Propanedioic acid, [[4-[2-[(2-naphthalenyl)oxy]ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)



RN 701979-48-8 CA

CN Propanedioic acid, [[4-[2-[(1,2,3,4-tetrahydro-7-quinolinyl)oxy]ethoxy]phenyl]methyl]-, monomethyl ester (9CI) (CA INDEX NAME)



IT 701294-93-1P 701294-97-5P 701295-01-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and saponification of; preparation of noncyclic 1,3-dicarbonyl compds. as dual PPAR agonists with antihyperglycemic and antihyperlipidemic activity)

RN 701294-93-1 CA


CN Benzenepropanoic acid, alpha-(aminocarbonyl)-4-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]ethoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of noncyclic 1,3-dicarbonyl compds. as dual PPAR agonists with antihyperglycemic and antihyperlipidemic activity)


RN 701294-92-0 CA

CN Propanedioic acid, [[4-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 701294-94-2 CA

CN Benzenepropanoic acid, alpha-(aminocarbonyl)-4-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]ethoxy]- (9CI) (CA INDEX NAME)




RN 701294-98-6 CA

CN Benzenepropanoic acid, alpha-(aminocarbonyl)-4-[2-[(2-naphthalenyl)oxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 701979-41-1 CA


CN Propanedioic acid, [[4-[2-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 701979-46-6 CA

10/713,722

L4 ANSWER 4 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)
CN Benzenepropanoic acid, α -(aminocarbonyl)-4-[2-(2-naphthalenyloxy)ethoxy]- (9CI) (CA INDEX NAME)



RN 701979-49-9 CA
CN Benzenepropanoic acid, α -(aminocarbonyl)-4-[2-[(1,2,3,4-tetrahydro-7-quinolinyloxy)ethoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 139:307663 CA
TITLE: Synthesis and insulin-sensitizing activity of a series of 2-benzyl-1,3-dicarbonyl derivatives
AUTHOR(S): Tang, Lei; Leng, Ying; Wang, Huo-Quan; Feng, Ying; Yang, Yu-Sha; Ji, Ru-Yun
CORPORATE SOURCE: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, P. Rep. China
SOURCE: Chinese Journal of Chemistry (2003), 21(4), 365-368
CODEN: CJOCEV; ISSN: 1001-604X
PUBLISHER: Science Press
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:307663
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A series of 2-benzyl-1,3-dicarbonyl derivs., e.g. I, was synthesized. Their insulin-sensitizing activity was evaluated in 3T3-L1 preadipocyte cells. Comps. I, II, and III were found to possess strong insulin-sensitizing activity in vitro and were selected for further hypoglycemic evaluation in vivo.

IT 610280-91-6P 610280-92-7P 610280-94-9P
610280-96-1P 610280-97-2P 610280-99-4P
610281-01-1P 610281-03-3P 610281-05-5P
610281-07-7P 610281-08-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and insulin-sensitizing activity of a series of 2-benzyl-1,3-dicarbonyl derivs.)

RN 610280-91-6 CA
CN Propanediamide, N,N'-dihydroxy-2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 610280-92-7 CA
CN Propanedioic acid, [[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, dihydrazide (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)




RN 610280-94-9 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]- α -[(2-pyridinylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 610280-96-1 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]- α -[(3-pyridinylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 610280-97-2 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]- α -[(4-pyridinylamino)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 610280-99-4 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]- α -[(2-pyridinylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)




RN 610281-01-1 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]- α -[(3-pyridinylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 610281-03-3 CA
CN Benzenepropanoic acid, 4-[2-(methyl-2-pyridinylamino)ethoxy]- α -[(4-pyridinylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 610281-05-5 CA
CN Propanediamide, N,N'-dimethyl-2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 610281-07-7 CA
CN Propanediamide, 2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-N,N'-diphenyl- (9CI) (CA INDEX NAME)



10/713,722

L4 ANSWER 5 OF 5 CA COPYRIGHT 2005 ACS on STN (Continued)

RN 610281-08-8 CA
CN Propanediamide, N,N'-dicyclopropyl-2-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/713,722

=> d his

(FILE 'HOME' ENTERED AT 14:18:31 ON 26 MAY 2005)

FILE 'REGISTRY' ENTERED AT 14:18:38 ON 26 MAY 2005

L1 STRUCTURE UPLOADED

L2 0 S L1 SAM

L3 31 S L1 FULL

FILE 'CA' ENTERED AT 14:19:48 ON 26 MAY 2005

L4 5 S L3

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 14:20:30 ON 26 MAY 2005